Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by OS Therapies

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040
From OS Therapies
Via Business Wire
Tickers OSTX
Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies FDA Meeting Request Granted
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Host Analyst Day at NYSE on April 7, 2025
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference
From OS Therapies
Via Business Wire
Tickers OSTX
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Present at The Spartan Capital Investor Conference
From OS Therapies
Via Business Wire
Tickers OSTX
Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Present at the LD Micro Main Event XVII
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Clarifies CUSIP of Common Stock
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS
From OS Therapies
Via Business Wire
Tickers OSTX
OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121 in Recurred, Resected Osteosarcoma with OST-HER2 (Listeria monocytogenes) for Delay or Prevention of Recurrence
From OS Therapies
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.